24/7 Market News Snapshot 09 July, 2025 – Calidi Biotherapeutics, Inc. (NYSE:CLDI)

July 9, 2025

DENVER, Colo., 09 July, 2025 (www.247marketnews.com) – (NYSE:CLDI) are discussed in this article.
Calidi Biotherapeutics, Inc. (NYSE American: CLDI), a prominent clinical-stage biotechnology company dedicated to advancing targeted genetic therapies for malignancies, is experiencing significant market interest. With its stock price rising dramatically, opening at $0.894 and soaring to a trading value of $0.805—reflecting a remarkable increase of over 140.30% from the previous close—Calidi has attracted attention from investors with an impressive trading volume of approximately 567.71 million shares, indicating robust market confidence in its innovative biotherapeutic solutions.

In a strategic financial maneuver, Calidi has announced the immediate exercise of outstanding warrants that will result in the issuance of 6,595,000 shares of common stock at a reduced exercise price of $0.70. This initiative is expected to generate around $4.6 million in gross proceeds, bolstering the firm’s funding as it advances its clinical and preclinical development programs. The terms of the agreement also include the provision of new unregistered warrants, which will allow for additional shares to be acquired in the future.

The capital raised from this warrant exercise will support Calidi’s ambitious clinical initiatives, including its proprietary Redtail platform, which has been in development for a decade. This innovative technology is designed to optimize viral vector delivery systems that circumvent immune detection, enhancing the effectiveness of virotherapies in targeting tumor sites, particularly in challenging cases such as non-small cell lung cancer and ovarian cancer.

Calidi Biotherapeutics remains committed to leveraging its advancements in biotechnology to develop impactful therapies that address significant unmet medical needs, reaffirming its strategic position within the biotechnology landscape as it pursues growth and innovation.

Related news for (CLDI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.